221 related articles for article (PubMed ID: 27544803)
1. p16 expression as a prognostic and predictive marker in high-grade localized osteosarcoma of the extremities: an analysis of 357 cases.
Righi A; Gambarotti M; Sbaraglia M; Sisto A; Ferrari S; Dei Tos AP; Picci P
Hum Pathol; 2016 Dec; 58():15-23. PubMed ID: 27544803
[TBL] [Abstract][Full Text] [Related]
2. p16 expression predicts neoadjuvant tumor necrosis in osteosarcomas: reappraisal with a larger series using whole sections.
Kosemehmetoglu K; Ardic F; Karslioglu Y; Kandemir O; Ozcan A
Hum Pathol; 2016 Apr; 50():170-5. PubMed ID: 26997452
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy.
Robl B; Pauli C; Botter SM; Bode-Lesniewska B; Fuchs B
BMC Cancer; 2015 May; 15():379. PubMed ID: 25956431
[TBL] [Abstract][Full Text] [Related]
4. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
5. Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.
Matsuda K; Miyoshi H; Hiraoka K; Hamada T; Nakashima K; Shiba N; Ohshima K
Clin Orthop Relat Res; 2018 Sep; 476(9):1848-1855. PubMed ID: 30024460
[TBL] [Abstract][Full Text] [Related]
6. p16 protein expression and correlation with clinical and pathological features in osteosarcoma of the jaws: Experience of 37 cases.
Asioli S; Righi A; Rucci P; Tarsitano A; Marchetti C; Bacchini P; Balbi T; Bertoni F; Foschini MP
Head Neck; 2017 Sep; 39(9):1825-1831. PubMed ID: 28560748
[TBL] [Abstract][Full Text] [Related]
7. P16INK4a overexpression and survival in osteosarcoma patients: a meta analysis.
Bu J; Li H; Liu LH; Ouyang YR; Guo HB; Li XY; Xiao T
Int J Clin Exp Pathol; 2014; 7(9):6091-6. PubMed ID: 25337256
[TBL] [Abstract][Full Text] [Related]
8. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy.
Borys D; Canter RJ; Hoch B; Martinez SR; Tamurian RM; Murphy B; Bishop JW; Horvai A
Hum Pathol; 2012 Nov; 43(11):1948-54. PubMed ID: 22578565
[TBL] [Abstract][Full Text] [Related]
9. A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification.
Jeys LM; Thorne CJ; Parry M; Gaston CL; Sumathi VP; Grimer JR
Clin Orthop Relat Res; 2017 Mar; 475(3):842-850. PubMed ID: 27138473
[TBL] [Abstract][Full Text] [Related]
10. Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?
Kubo T; Shimose S; Fujimori J; Furuta T; Arihiro K; Ochi M
Clin Orthop Relat Res; 2015 Jan; 473(1):305-10. PubMed ID: 25193692
[TBL] [Abstract][Full Text] [Related]
11. P16 protein expression as a useful predictive biomarker for neoadjuvant chemotherapy response in patients with high-grade osteosarcoma: A systematic meta-analysis under guideline of PRISMA.
Tang Y; Yang C; Guo Z; Fu Y; Yu X; Liu B; Zhou H; Wang J; Li W; Pang Q
Medicine (Baltimore); 2017 May; 96(19):e6714. PubMed ID: 28489748
[TBL] [Abstract][Full Text] [Related]
12. Proximal tumor location and fluid-fluid levels on MRI predict resistance to chemotherapy in stage IIB osteosarcoma.
Jeon DG; Song WS; Cho WH; Kong CB; Cho SH
Clin Orthop Relat Res; 2014 Jun; 472(6):1911-20. PubMed ID: 24574120
[TBL] [Abstract][Full Text] [Related]
13. Is Microscopic Vascular Invasion in Tumor Specimens Associated with Worse Prognosis in Patients with High-grade Localized Osteosarcoma?
Tsuda Y; Tsoi K; Stevenson JD; Parry MC; Fujiwara T; Sumathi V; Jeys LM
Clin Orthop Relat Res; 2020 Jun; 478(6):1190-1198. PubMed ID: 31904683
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
Bielack SS; Smeland S; Whelan JS; Marina N; Jovic G; Hook JM; Krailo MD; Gebhardt M; Pápai Z; Meyer J; Nadel H; Randall RL; Deffenbaugh C; Nagarajan R; Brennan B; Letson GD; Teot LA; Goorin A; Baumhoer D; Kager L; Werner M; Lau CC; Sundby Hall K; Gelderblom H; Meyers P; Gorlick R; Windhager R; Helmke K; Eriksson M; Hoogerbrugge PM; Schomberg P; Tunn PU; Kühne T; Jürgens H; van den Berg H; Böhling T; Picton S; Renard M; Reichardt P; Gerss J; Butterfass-Bahloul T; Morris C; Hogendoorn PC; Seddon B; Calaminus G; Michelagnoli M; Dhooge C; Sydes MR; Bernstein M;
J Clin Oncol; 2015 Jul; 33(20):2279-87. PubMed ID: 26033801
[TBL] [Abstract][Full Text] [Related]
15. Cell Cycle Checkpoints p16 and p21-Strong Predictors of Clinicopathologic Outcomes in High-Grade Osteosarcoma.
Nasri E; Torrence DE; Vasilopoulos T; Knapik JA; Lagmay JP; Reith JD; Gibbs CP
Cancer J; 2024 May-Jun 01; 30(3):133-139. PubMed ID: 38753746
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a pretreatment prognostic index to predict death and lung metastases in extremity osteosarcoma.
Wang B; Tu J; Yin J; Zou C; Wang J; Huang G; Xie X; Shen J
Oncotarget; 2015 Nov; 6(35):38348-59. PubMed ID: 26435480
[TBL] [Abstract][Full Text] [Related]
19. The extremity localized classic osteosarcomas have better survival than the axial non-classics.
Lin L; Deng S; Zhang F; Liang Y; Huang Z
World J Surg Oncol; 2018 Feb; 16(1):39. PubMed ID: 29471883
[TBL] [Abstract][Full Text] [Related]
20. Postrelapse Prognostic Factors in Nonmetastatic Osteosarcoma: A Single-institution Experience.
Berlanga P; Cañete A; Salom M; Montalar J; Guasp M; Marco A; Castel V
J Pediatr Hematol Oncol; 2016 Apr; 38(3):176-81. PubMed ID: 26925713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]